University of Oxford Announces Opening of PanDox Phase 1 Study investigating Targeted Drug Delivery by Focused Ultrasound for Pancreatic Cancer
The University of Oxford is pleased to announce commencement of enrolment for the Phase I PanDox study of thermosensitive liposomal doxorubicin triggered by focused ultrasound in patients with pancreatic cancer.
This investigator-led study sponsored by the University of Oxford and supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre has now received ethics, MHRA and institutional R&D approval to commence (ClinicalTrials.gov Identifier: NCT04852367).
PanDox is being carried out as a multi-disciplinary collaboration between the Oxford University Institute of Biomedical Engineering, the Oncology Clinical Trials Office (OCTO), the Oxford University Hospitals NHS Foundation Trust, and Celsion corporation, the manufacturer of the proprietary heat-activated liposomal encapsulation of doxorubicin ThermoDox® used in the study. Prof. Mark Middleton, MD, Head of the Department of Oncology at the University of Oxford is the chief clinical investigator and Prof. Constantin Coussios, FREng, PhD, Director of the Institute of Biomedical Engineering, is the lead scientific investigator.
The primary endpoint of the two-arm 18-subject PanDox study is enhanced uptake of doxorubicin in pancreatic tumours using thermosensitive liposomal doxorubicin and Focused Ultrasound (FUS), compared to systemic delivery of free doxorubicin.
ThermoDox® will be administered intravenously in 12 patients with non-resectable pancreatic duct adenocarcinoma (PDAC) and locally activated by focused ultrasound-mediated hyperthermia. This will be compared to conventional systemic delivery of doxorubicin without FUS in 6 patients.
Secondary endpoints include:
- Comparing radiologically assessed tumour activity and response with thermosensitive liposomal doxorubicin and FUS to free drug alone.
- Examining the impact on patient symptoms of ThermoDox® plus FUS.
- Assessing the safety profile of both FUS and ThermoDox®.
The study is expected to be completed by December 2022 and is similar in design to Oxford’s 10-patient TARDOX study, which demonstrated that ThermoDox® plus focused ultrasound increased doxorubicin tumour concentrations by up to 10-fold and enhanced nuclear drug uptake in patients with liver tumours. The findings of the TARDOX study are published in Lancet Oncology (Lyon et al., 2018) and Radiology (Gray et al., 2019).
Preclinical studies conducted at the University of Washington and published in the International Journal of Hyperthermia describe similarly compelling results from experiments performed in a murine model of pancreatic cancer. Those studies demonstrated that ThermoDox® plus focused ultrasound increased localized concentration and nuclear uptake of doxorubicin 23-fold compared with a 2-fold increase for hyperthermia and free doxorubicin.
Commenting on the PanDox clinical study, Dr Laura Spiers, lead oncology clinical research fellow on the PanDox study, said: ‘Pancreatic cancer has a low five-year survival rate of approximately 10% and drug-based treatments remain less effective than in other cancers, in part due to the unique challenges presented by the stroma surrounding pancreatic tumours. Therefore, finding innovative and effective means of delivering high concentrations of anti-cancer agents such as doxorubicin may lead to a breakthrough for this difficult-to- treat cancer.’
Dr Mike Gray, lead biomedical engineering research fellow, said: ‘Based on the patient-specific treatment planning approaches developed and validated during the TARDOX trial, PanDox will deliver focused ultrasound mild hyperthermia without either MR-based or invasive thermometry. The aim therefore is to develop a cost-effective and scalable approach that can be rapidly deployed for the benefit of pancreatic patients.’